Free tool
FAERS Monitor: Cosela
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214200 or its brand name (Cosela, Trilaciclib Dihydrochloride). Reports on generic versions are filed under their own applications.
Reports
244
Serious
136
56% of reports
Hospitalization
80
Death reported
25
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- myelosuppression37
- off label use27
- dyspnoea19
- white blood cell count decreased19
- platelet count decreased18
- death16
- pneumonia15
- anaemia14
- performance status decreased14
- fatigue13
- nausea13
- infection12
- chest discomfort11
- haemorrhage11
- infusion site pain11
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2021 | 28 |
| 2022 | 67 |
| 2023 | 63 |
| 2024 | 18 |
| 2025 | 50 |
| 2026 | 17 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,915 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| performance status decreasedSignal | 14 | 259.4 | 155.9 | 3,341 |
| myelosuppressionSignal | 37 | 88.6 | 65.9 | 3,121 |
| infusion site painSignal | 11 | 73.6 | 41.3 | 717 |
| white blood cell count decreasedSignal | 19 | 15.1 | 9.8 | 238 |
| platelet count decreasedSignal | 18 | 14.6 | 9.3 | 215 |
| chest discomfortSignal | 11 | 9.3 | 5.2 | 73 |
| haemorrhageSignal | 11 | 9.1 | 5.1 | 71 |
| infectionSignal | 12 | 7.1 | 4.1 | 58 |
| anaemiaSignal | 14 | 6.3 | 3.8 | 58 |
| pneumoniaSignal | 15 | 4.0 | 2.4 | 31 |
| dyspnoeaSignal | 19 | 2.9 | 1.9 | 22 |
| off label useSignal | 27 | 2.7 | 1.9 | 27 |
| death | 16 | 1.6 | 1.0 | 3 |
| fatigue | 13 | 1.4 | 0.8 | 1 |
| nausea | 13 | 1.4 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.